OBI 833

Drug Profile

OBI 833

Alternative Names: Globo H-CRM 197; OBI-833; OBI-833/OBI-821

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Academia Sinica
  • Developer OBI Pharma
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in Taiwan (SC)
  • 11 Dec 2014 Preclinical trials in Solid tumours in Taiwan (SC)
  • 11 Dec 2014 Optimer Biotechnology plans a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in Taiwan and USA (NCT02310464)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top